CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): Results of an interim safety and efficacy analysis
DOI 10.1055/s-2005-920176
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Porschen, HT Arkenau, S Kubicka, T Seufferlein, U Graeven, P Freier, A Grothey, A Hinke, HJ Schmoll, C Englisch-Fritz
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe04/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: In a previous phase III study the FUFOX regimen has shown superior response rates to bolus 5-FU/FA (Mayo Clinic protocol) in patients with MCRC (Grothey, ASCO 2002). The combination of capecitabine (CAP) and oxaliplatin (OX) has demonstrated good efficacy and safety results in recent phase II studies. In August 2002 we initiated a phase III trial to compare FUFOX and CAPOX as first line therapy in patients wit…
Zitieren
Zitierempfehlung
R Porschen, HT Arkenau, S Kubicka, T Seufferlein, U Graeven, P Freier, A Grothey, A Hinke, HJ Schmoll, C Englisch-Fritz (2006) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): Results of an interim safety and efficacy analysis. Zeitschrift für Gastroenterologie (04). https://doi.org/10.1055/s-2005-920176
Mit CareLit weiterarbeiten